Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544082 | 0.87 | CYP3A4 (0.45) | TLR8TLR7TLR9PLATCYP3A4 | |
| SCHEMBL4946154 | 0.85 | HPGD (0.39) | TLR8TLR7TLR9CYP3A4MEN1 | |
| SCHEMBL1545085 | 0.76 | KCNH2 (0.54) | CYP3A4MEN1KMT2A | |
| SCHEMBL5760939 | 0.74 | GRM5 (0.53) | CYP3A4MEN1KMT2A | |
| SCHEMBL1543960 | 0.73 | KMT2A (0.45) | MEN1KMT2A | |
| SCHEMBL1543424 | 0.72 | KMT2A (0.44) | TLR8TLR7TLR9CYP3A4MEN1 | |
| SCHEMBL1544707 | 0.72 | MEN1 (0.40) | TLR8TLR7TLR9HDAC6MEN1 | |
| SCHEMBL1543704 | 0.72 | KCNH2 (0.41) | TLR8TLR7TLR9HDAC6 | |
| SCHEMBL1544436 | 0.72 | KCNH2 (0.54) | TLR8TLR7TLR9MEN1KMT2A | |
| Pyridine SCHEMBL1544776 | 0.71 | KMT2A (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456200-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-11-25 | — | — | US | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | TLR8 820/4885TLR7 628/4885TLR9 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.